Imatinib-Teva
Imatinib-Teva is a generic from Teva Pharma AG and is listed on the FOPH Specialities List. Basic health insurance reimburses it within the authorised indication. The public price ranges from CHF 518.95 to CHF 1'020.45 depending on the pack; the co-payment is 10 per cent.
Core data
- Authorisation holder
- Teva Pharma AG
- ATC code
- L01EA01
- IT group
- 07.16.10 Cytostatica
- Active substances
- Imatinibum
- Preparation type
- Generic
- On the SL since
- 01/07/2016
- Last price change
- 01/12/2020
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Filmtabl 100 mg | 60 Stk | CHF 462.06 | CHF 518.95 | 01/07/2016 | A | 7680651550012 |
| Filmtabl 400 mg | 30 Stk | CHF 923.22 | CHF 1'020.45 | 01/07/2016 | A | 7680651550029 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
Behandlung von Erwachsenen mit Ph+ akuter lymphatischer Leukämie (Ph+ALL) in Kombination mit Standardchemotherapie.
Behandlung von erwachsenen Patienten mit Hypereosinophilensyndrom (HES), atypischen myelodysplastischen/myeloproliferativen Erkrankungen (MDS/MPD) oder aggressiver systemischer Mastozytose (SM) einhergehend mit Eosinophilie und einer plated-derived growth factor (PDGF)-Rezeptor-alpha oder -beta Mutation oder einem FIP1L1-PDGFR-alpha Fusionsprotein.
Behandlung von Erwachsenen mit unresezierbarem, rezidivierendem oder metastasierendem Dermatofibrosarkom protuberans (DFSP).
More preparations in this group
FAQ
Is Imatinib-Teva covered by Swiss health insurance?
Yes, but only under conditions. Imatinib-Teva is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Imatinib-Teva cost in Switzerland?
The public price is the maximum price set by the FOPH and for Imatinib-Teva ranges from CHF 518.95 to CHF 1'020.45 per pack. The ex-factory price ranges from CHF 462.06 to CHF 923.22. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages